Carisma Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
The company is advancing engineered myeloid cell therapies, with a focus on mesothelin-targeted CT-1119 for solid tumors and TIM4-based CT-2401 for liver fibrosis. Key milestones include a Phase 1 trial for CT-1119 and a development candidate for fibrosis, with strong industry partnerships supporting progress.
-
The conference detailed advances in CAR-macrophage therapies for oncology, fibrosis, and autoimmune diseases, highlighting a shift to in vivo reprogramming and key partnerships. Major milestones include upcoming clinical trials for CT2401 and CT1119, and ongoing collaboration with Moderna on multiple targets.
Fiscal Year 2024
-
The company is advancing engineered macrophage therapies for oncology and fibrosis, with a lead HER2-targeted CAR monocyte program in dose escalation and data expected in Q1. Strategic partnerships, notably with Moderna, are expanding the pipeline into in vivo and autoimmune applications.
-
The company is advancing engineered macrophage therapies across oncology, autoimmune, and fibrosis, with a lead HER2-targeted program in phase I and a major in vivo collaboration with Moderna. Key data readouts and development milestones are expected by year-end and into next year.
-
Four main therapeutic areas are advancing, with lead oncology and fibrosis programs nearing key milestones. Engineered macrophages and monocytes show promise in tumor targeting and fibrosis, supported by a strategic Moderna partnership.
-
The discussion highlighted advances in engineered macrophage therapies, with CT-0525 showing improved tumor infiltration and persistence over earlier candidates. The Moderna partnership is advancing in vivo CAR-M for liver cancer, and preclinical data in fibrosis are promising.
-
The conference highlighted advances in engineered myeloid cell therapies, with a shift to CAR monocytes for improved efficacy, manufacturing, and persistence. Early clinical and preclinical data show promise in oncology and liver fibrosis, with key milestones expected by year-end.